{"id":"NCT03386474","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD","officialTitle":"A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-15","primaryCompletion":"2018-09-06","completion":"2018-09-06","firstPosted":"2017-12-29","resultsPosted":"2020-04-30","lastUpdate":"2021-01-05"},"enrollment":151,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Brolucizumab 6 mg","otherNames":["RTH258"]},{"type":"DRUG","name":"Aflibercept 2 mg","otherNames":["EYELEA"]}],"arms":[{"label":"Brolucizumab","type":"EXPERIMENTAL"},{"label":"Aflibercept","type":"OTHER"}],"summary":"The purpose of this extension study was to assess the safety and efficacy of the new formulation of brolucizumab 6 mg ophthalmic solution when given to the same patients who received brolucizumab in the core trial CRTH258A2301 (also known as CRTH258-C002). The medical condition treated in the core and extension trials was neo-vascular age-related macular degeneration (nAMD).","primaryOutcome":{"measure":"Number of Participants With Ocular and Non-Ocular Treatment Emergent Adverse Events","timeFrame":"Up to Week 24","effectByArm":[{"arm":"Brolucizumab - Overall Extension Study","deltaMin":20,"sd":null},{"arm":"Brolucizumab Overall Last 6 Months From Core Study","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":65,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=293"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":107},"commonTop":["Urinary tract infection","Nasopharyngitis","Neovascular age-related macular degeneration - Fellow eye","Cataract - Fellow eye","Haematuria"]}}